Tags : Three-year

Bluebird Bio Signs a Three-Year Research Collaboration with Novo Nordisk

Shots: Bluebird Bio to utilize its mRNA-based megaTAL technology providing a specific and efficient way to silence, edit or insert genetic components combining Novo Nordisk’s deep expertise in hemophilia research and therapeutics  The focus of the collaboration is to identify gene therapy candidates for people with severe genetic diseases with initial interest of correcting FVIII-clotting […]Read More

GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell

Shots: Hitachi Chemical’s subsidiary HCATS (Hitachi Chemical Advanced Therapeutics Solutions), will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials The agreement focuses on providing, compliant, flexible, scalable, and cost-effective therapies accessible to cancer patients NY-ESO-1 is a human tumor antigen expressed in sarcomas, melanoma, multiple myeloma, bladder cancer, […]Read More